Navigation Links
Halozyme Reports First Quarter 2012 Financial Results
Date:5/7/2012

ivities. 
  • Selling, general and administrative (SG&A) expenses for the first quarter of 2012 were $6.6 million, compared to $3.4 million for the first quarter of 2011. The increase for SG&A was due to higher compensation costs and higher marketing and market research expenses during the quarter. 
  • Cash and cash equivalents were $116.6 million as of March 31, 2012, compared with $73.8 million as of March 31, 2011. Excluding the net proceeds of $81.5 million from the financing in February 2012, net cash used in the first quarter of 2012 was approximately $17.7 million.
  • Due to the HyQ regulatory delay, we anticipate 2012 cash burn to be $55-$60 million, instead of $50-$55 million as previously forecasted.

    Conference CallHalozyme will webcast its Quarterly Update Conference Call today at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, Ph.D., Halozyme's President and Chief Executive Officer, will lead the call. During the call, the Company plans to provide further details underlying its first quarter 2012 financial results. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 393124.

    Upcoming Corporate PresentationsHalozyme is scheduled to present at the upcoming investor conference.

  • Bank of America Merrill Lynch 2012 Healthcare Conference in Las Vegas on May 16, 2012 at 1:00 p.m. ET/10:00 a.m. PT. Gregory I. Frost, Ph.D., President and Chief Executive Officer of Halozyme Therapeutics, will p
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    2. ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
    3. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
    4. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
    5. Halozyme Announces Proposed Public Offering of Common Stock
    6. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
    7. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
    8. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
    9. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
    10. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
    11. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/30/2015)... SAN DIEGO, April 30, 2015  Tandem Diabetes Care ® ... and manufacturer of the t:slim ® and t:flex™ Insulin ... March 31, 2015. In comparing the first ... , Sales grew 53 percent to $12.3 million from $8.1 ... 2,487 pumps from 1,723 pumps "Our investment in ...
    (Date:4/30/2015)... , April 30, 2015   Regulus Therapeutics ... leading the discovery and development of innovative medicines targeting ... and highlights for the quarter ended March 31, 2015 ... markets close. Regulus will host a ... at 5:00 pm Eastern Daylight Time to discuss its ...
    (Date:4/30/2015)... (Nasdaq: DRRX ) announced today financial results for ... million and net loss was $4.9 million for the ... total revenues of $6.3 million and net loss of ... 2014.At March 31, 2015, we had cash and investments ... $34.9 million at December 31, 2014.  Subsequent to quarter-end, ...
    Breaking Medicine Technology:Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 9
    ... 2012  At the 2012 American Association of Neurological ... the Miami Beach Convention Center, Elekta (booth #725) ... Knife® Perfexion™ that promise to enhance information ... us the opportunity to demonstrate to neurological surgeons ...
    ... PITTSBURGH, April 13, 2012 Mylan Inc. (Nasdaq: ... Pharmaceuticals Inc. has received final approval from the U.S. ... Drug Application (ANDA) for Fluvastatin Capsules USP, 20 mg ... Lescol ® Capsules. This product is indicated for ...
    Cached Medicine Technology:Elekta to Unveil New Neuroscience Solution for Leksell Gamma Knife at 2012 AANS Meeting 2Mylan Launches First Generic Version of Lescol® Capsules 2
    (Date:5/3/2015)... 03, 2015 It is not too late to ... Walk in Memory of Lissa Anne Been in Arnold, Missouri ... great family-friendly event to honor her loving memory. It has benefited ... , Just having turned 37, Lissa suffered a brain aneurysm ... August 24, 2012. This event is designed to serve as a ...
    (Date:5/2/2015)... 02, 2015 “ ActOn ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... connected with organizations to make a difference. , In this ... few things that aren’t about money, which is why those ...
    (Date:5/2/2015)... Liverpool, Ohio (PRWEB) May 02, 2015 ... East Liverpool City Hospital (ELCH) gathered to celebrate improvements ... of River Valley Health Partners (RVHP), had zero acquired ... zero urinary catheter associated infections. ELCH was also recently ... , The management team at ELCH credited the teamwork ...
    (Date:5/1/2015)... (PRWEB) May 02, 2015 IDLife LLC, ... is proud to announce the addition of its newest ... is a life long athlete, growing up in gymnastics ... after college by becoming a personal trainer and helping ... the face of several TV shows highlighting her stunning ...
    (Date:5/1/2015)... Va. (PRWEB) May 01, 2015 The ... nation’s leading nonprofit authority on the use of health ... as a key contributing resource to the United States ... use of electronically readable cards in Medicare. The report, ... and Providers ” was released to the public on ...
    Breaking Medicine News(10 mins):Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3
    ... five whites could carry a genetic variant that substantially increases ... to new research. This genetic variant, characterized by one ... response to specific chemical signals. In the study, led by ... more than threefold increase in the odds that carriers will ...
    ... HealthDay Reporter , MONDAY, Dec. 20 (HealthDay News) -- New research ... -- contain a fatty acid that may lower the risk of ... according to the study in the Dec. 21 issue of the ... blood levels of this fatty acid reduce their odds of diabetes ...
    ... TUESDAY, Dec. 21 (HealthDay News) -- Judy Brown says she has ... Brown, now 51 and living in Nashua, N.H., remembers being ... come on, even though she didn,t understand at the time what ... she said. "Sometimes it would be a car, a back seat ...
    ... people with early stage liver cancer were more likely than ... new study from the University of Michigan Comprehensive Cancer Center. ... cancer patients were alive but only 15 percent of Hispanic ... times ranged from 10 months for whites and Hispanics to ...
    ... monitoring helped push cure rates to nearly 88 percent ... Research Hospital acute lymphoblastic leukemia (ALL) treatment protocol and ... battling the most common childhood cancer. A report ... of Clinical Oncology noted that overall survival jumped 30 ...
    ... By Steven Reinberg HealthDay Reporter , MONDAY, ... among Americans, a new study shows, despite reported links to ... safe "spray-on" tans. In fact, about one in every ... they use indoor tanning, University of Minnesota researchers report. ...
    Cached Medicine News:Health News:Genetic trait could triple odds of whites' susceptibility to heavy cocaine abuse 2Health News:Genetic trait could triple odds of whites' susceptibility to heavy cocaine abuse 3Health News:Genetic trait could triple odds of whites' susceptibility to heavy cocaine abuse 4Health News:Whole-Fat Dairy Products May Lower Type 2 Diabetes Risk: Study 2Health News:Whole-Fat Dairy Products May Lower Type 2 Diabetes Risk: Study 3Health News:A Lifetime of Migraines 2Health News:Blacks with liver cancer more likely to die, study finds 2Health News:Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients 2Health News:Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients 3Health News: Tanning Beds Still Popular Despite Skin Cancer Risk 2Health News: Tanning Beds Still Popular Despite Skin Cancer Risk 3
    ... basic Thermomixer is a compact model that ... x 1.5 ml tubes. Impressive features of ... design, and high stabilityeven at maximum mixing ... gentle to vigorous mixing, including intermittent mixing; ...
    ... ug Strept. 25 ug Fungizone ... and Buffer products are manufactured ... and are cell culture tested ... Properties, Sterility : Neg. , ...
    ... 25,000 units Penicillin/25,000 ... Cell Culture Reagent and ... in accordance with cGMP ... culture tested to assure ...
    Penicillin-Streptomycin-Glutamine (100X) liquid...
    Medicine Products: